Retatrutide 20mg (R&D Only) Designed exclusively for laboratory research
GLP-1 and Fatty Liver Disease (NAFLD/NASH) GLP-1RAs show promising benefits in: Hepatic steatosis reduction Weight loss-mediated liver improvement Improved insulin resistance Reduced inflammation These agents are likely to become central therapies in metabolic-associated steatotic liver disease (MASLD)
To be eligible, patients must: Be 18 years or older and not pregnant Have a Body Mass Index (BMI) of 30 kg/m to qualify for any of the medications, or Have a BMI of 27 kg/m with at least one weight-related risk factor (e.g., high blood pressure, type 2 diabetes, high cholesterol) to start Phentermine, Phentermine +Topiramate, Metformin, or compounded Tirzepatide, or Have a BMI of 25 kg/m with at least one weight-related risk factor (e.g
I lost 67 pounds, and I feel like a new person
XuBGouldingEHZangKCepoiDConeRDJonesKRet al
Video visits and managed titration: MyStart Health